-
公开(公告)号：US20100184083A1
公开(公告)日：2010-07-22
申请号：US12439744
申请日：2007-09-04
IPC分类号： G01N33/53
CPC分类号： G01N33/5044 , G01N33/57488 , G01N33/6887
摘要： The present invention is directed to methods of detecting viable epithelial cells in a sample. The method includes isolating the sample comprising cells from a patient and culturing the cells for a time sufficient for an epithelial cell-specific marker to be released from the cells. The marker includes a substantially full-length cytokeratin. The method further includes detecting the released marker. Detection of the marker indicates the presence of disseminated epithelial cells. Methods are also directed to identifying disseminated epithelial tumor cells.
摘要翻译： 本发明涉及检测样品中活细胞上皮细胞的方法。 该方法包括从患者中分离包含细胞的样品，并培养细胞足以使上皮细胞特异性标志物从细胞释放的时间。 标记物包括基本全长的细胞角蛋白。 该方法还包括检测释放的标记。 标志物的检测表明存在播散性上皮细胞。 方法还涉及鉴定弥散性上皮肿瘤细胞。
-
公开(公告)号：US20210139563A1
公开(公告)日：2021-05-13
申请号：US17052484
申请日：2019-05-02
发明人： Friedrich Nolte , Anna Marei Mann
IPC分类号： C07K16/08 , C07K16/28 , C07K14/005 , C12N7/00 , C12N15/86
摘要： The present invention relates to fusion proteins comprising a cell surface marker specific VHH. In particular, the invention relates to bispecific VHH adaptor proteins, i.e. fusion proteins comprising an adeno-associated virus (AAV) specific VHH linked to a cell surface marker specific VHH. Moreover, the invention relates to a recombinant AAV which comprises a fusion protein in which a cell surface marker specific VHH is integrated into a capsid protein of the AAV. Also nucleotide sequences encoding such fusion proteins, vectors are contemplated. The invention moreover refers to uses of the fusion proteins and nucleic sequences for gene therapy.
-
3.发明申请CIRCULATING miRNAs AS NON-INVASIVE MARKERS FOR DIAGNOSIS AND STAGING IN PROSTATE CANCER 审中-公开将miRNA作为非侵入性标志物进行诊断和分期检查在前列腺癌公开(公告)号：US20120264638A1
公开(公告)日：2012-10-18
申请号：US13502704
申请日：2010-10-29
申请人： Jan Christoph Brase , Holger Sültmann , Ruprecht Kuner , Marc Johannes , Tim Beissbarth , Maria Fälth , Thorsten Schlomm , Alexander Haese , Thomas Steuber
发明人： Jan Christoph Brase , Holger Sültmann , Ruprecht Kuner , Marc Johannes , Tim Beissbarth , Maria Fälth , Thorsten Schlomm , Alexander Haese , Thomas Steuber
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/156 , C12Q2600/178
摘要： The present invention relates to a method for staging prostate cancer in a subject suffering from prostate cancer, said method comprises (a) determining the amount of at least one miRNA selected from the group consisting of miRNA-375, miRNA-141, miRNA-200b, miRNA-516a-3p and miRNA9*, or the amount of a precursor molecule in a sample from said patient and (b) comparing the, thus, determined amount with a reference amount. Moreover, the present invention is concerned with a method for identifying a subject susceptible to prostate cancer therapy and to a method for diagnosing prostate cancer. Further envisaged by the present invention are a kit and a device adapted to carry out the method of the present invention.
摘要翻译： 本发明涉及一种用于在患有前列腺癌的受试者中分期前列腺癌的方法，所述方法包括（a）测定从miRNA-375，miRNA-141，miRNA-200b组成的组中选择的至少一种miRNA的量 ，miRNA-516a-3p和miRNA9 *，或来自所述患者的样品中的前体分子的量，和（b）将所确定的量与参考量进行比较。 此外，本发明涉及用于鉴定易患前列腺癌治疗的受试者的方法以及用于诊断前列腺癌的方法。 本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。
-
公开(公告)号：US20100167373A1
公开(公告)日：2010-07-01
申请号：US12514431
申请日：2007-11-11
CPC分类号： A61F2/2481 , A61F2240/001 , A61K35/34 , A61L27/38 , A61L27/54 , A61L2300/412 , A61L2300/414
摘要： The invention is directed to a pouch-like construct comprising mammalian tissue which can be used for preventing distension and/or resisting dilation of the heart in a mammal. Preferably, the pouch-like tissue construct has contractile properties. The invention further relates to a method for the preparation of a pouch-like construct comprising mammalian tissue which can be used for the above purposes.
摘要翻译： 本发明涉及包含哺乳动物组织的袋状构造体，其可用于预防哺乳动物心脏扩张和/或抵抗扩张。 优选地，袋状组织构造体具有收缩性。 本发明还涉及一种制备包含可用于上述目的的哺乳动物组织的袋状构建体的方法。
-
5.发明申请Method for carrying out the ex vivo expansion and ex vivo differentiation of multipotent stem cells 审中-公开进行多潜能干细胞体外扩增和离体分化的方法公开(公告)号：US20060051330A1
公开(公告)日：2006-03-09
申请号：US10497101
申请日：2002-11-22
申请人： Dieter Hossfeld , Walter Fielder , Ursula Gehling , Sonja Loges
发明人： Dieter Hossfeld , Walter Fielder , Ursula Gehling , Sonja Loges
CPC分类号： C12N5/0618 , A61K35/12 , A61K2035/124 , C12N5/0607 , C12N5/0647 , C12N5/067 , C12N5/069 , C12N2500/25 , C12N2500/60 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/12 , C12N2501/125 , C12N2501/13 , C12N2501/14 , C12N2501/15 , C12N2501/165 , C12N2501/26 , C12N2501/39 , C12N2503/00 , C12N2506/03 , C12N2506/11 , C12N2510/00
摘要： The invention relates to a method for carrying out the expansion of multipotent stem cells ex vivo. Moreover, the invention relates to a two-stage method for carrying out the expansion and differentiation of multipotent stem cells ex vivo, in which it is possible for the stem cells to be gene transfected during the first stage, i.e. during the expansion phase. In this phase, the differentiation of the multipotent stem cells takes place optionally in cells of the hematopoietic, endothelial or mesenchymal cell lineage. Stem and progenitor cells as well as mature cells of the hematopoietic, endothelial and mesenchymal cell lineage, which are obtained in this way, can be used, among other things, for the prophylaxis, diagnosis and therapy of human deseases and for tissue engineering.
摘要翻译： 本发明涉及离体多功能干细胞扩增的方法。 此外，本发明涉及用于离体扩增和分化多能干细胞的两阶段方法，其中干细胞在第一阶段期间即在扩增阶段期间可以进行基因转染。 在该阶段，多能干细胞的分化任选地在造血，内皮细胞或间充质细胞系的细胞中进行。 干细胞和祖细胞以及以这种方式获得的造血内皮和间充质细胞系的成熟细胞可以用于预防，诊断和治疗人类疾病和组织工程。
-
公开(公告)号：US08101352B2
公开(公告)日：2012-01-24
申请号：US12305258
申请日：2007-06-26
申请人： Guido Sauter , Ronald Simon , Phillip Stahl , Frederik Holst , Khawla Al-Kuraya , Christian Ruiz
发明人： Guido Sauter , Ronald Simon , Phillip Stahl , Frederik Holst , Khawla Al-Kuraya , Christian Ruiz
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106
摘要： The present invention relates to an in-vitro method of identifying a tumor resulting from a proliferative breast disease as responsive to anti-estrogen treatment. Further, the invention relates to an in-vitro method of identifying a candidate patient with a proliferative breast disease as suitable for anti-estrogen treatment. In a further aspect, the invention provides an in-vitro method of identifying an individual with a non-cancerous proliferative breast disease who is at risk of developing breast cancer. The invention also provides kits for performing the above methods.
摘要翻译： 本发明涉及鉴定由抗雌激素治疗反应的增殖性乳腺疾病引起的肿瘤的体外方法。 此外，本发明涉及鉴定具有适合于抗雌激素治疗的增殖性乳腺疾病的候选患者的体外方法。 在另一方面，本发明提供了一种鉴定患有具有发展为乳腺癌风险的非癌性增殖性乳腺疾病的个体的体外方法。 本发明还提供了用于执行上述方法的试剂盒。
-
7.发明申请公开(公告)号：US20100210612A1
公开(公告)日：2010-08-19
申请号：US12595017
申请日：2008-02-15
申请人： Ronald Simon , Guido Sauter , Luigi Terracciano , Frederik Holst , Annette Lebeau , Andreas Turzynski
发明人： Ronald Simon , Guido Sauter , Luigi Terracciano , Frederik Holst , Annette Lebeau , Andreas Turzynski
IPC分类号： A61K31/135 , A61P35/00 , C12Q1/68 , A61K31/58 , A61K31/4535
CPC分类号： C12Q1/6886 , C12Q2600/106
摘要： The present invention relates to an in-vitro method of identifying a tumor resulting from a proliferative disease of the endometrium or ovary as responsive to anti-estrogen treatment. Further, the invention relates to an in-vitro method of identifying a candidate patient with a proliferative disease of the endometrium or ovary as suitable for anti-estrogen treatment. In a further aspect, the invention provides an in-vitro method of identifying an individual with a non-cancerous proliferative disease of the endometrium or ovary who is at risk of developing endometrial or ovarian cancer. The invention also provides kits for performing the above methods.
摘要翻译： 本发明涉及鉴定由抗雌激素治疗反应的子宫内膜或卵巢的增殖性疾病产生的肿瘤的体外方法。 此外，本发明涉及鉴定适合于抗雌激素治疗的子宫内膜或卵巢的增殖性疾病的候选患者的体外方法。 在另一方面，本发明提供了一种鉴定具有子宫内膜或卵巢的非癌性增殖性疾病的个体的体外方法，所述子宫内膜或卵巢处于发展子宫内膜或卵巢癌的风险中。 本发明还提供了用于执行上述方法的试剂盒。
-
8.发明申请Use of Tri-Substituted Glycerol Compounds for the Treatment of Hematological Malignancies 审中-公开使用三取代甘油化合物治疗血液恶性肿瘤公开(公告)号：US20100136029A1
公开(公告)日：2010-06-03
申请号：US12520354
申请日：2007-11-09
IPC分类号： A61K31/661 , A61P35/00 , A61P35/02 , A61K33/24 , A61K31/704 , A61K39/395 , C12Q1/68
CPC分类号： A61K31/661 , A61K31/4965 , A61K31/513 , A61K31/52 , A61K31/685 , A61K31/7048 , A61K39/39533 , A61K45/06 , C07F9/091 , A61K2300/00
摘要： The present invention relates to the use of a tri-substituted glycerol compound for the manufacture of a medicament for the treatment of hematological malignancies. The invention also refers to a kit-of-parts comprising such a medicament. Finally, the invention also relates to a corresponding method for the treatment of such conditions as well as to an in vitro method for determining the susceptibility of such malignant cells to a medicament as defined in the invention.
摘要翻译： 本发明涉及三取代甘油化合物在制备用于治疗血液恶性肿瘤的药物中的用途。 本发明还涉及包含这种药物的成套工具。 最后，本发明还涉及用于治疗这些病症的相应方法以及用于确定这样的恶性细胞对本发明所定义的药物敏感性的体外方法。
-
9.发明申请公开(公告)号：US20090006043A1
公开(公告)日：2009-01-01
申请号：US12151306
申请日：2008-05-06
CPC分类号： G09B23/28
摘要： The object of the instant invention is a method for simulating the haptics of an interaction of an object guided by a user, hereinafter referred to as tool, with a virtual three-dimensional object, in particular the scanning of the surface of the simulated object and/or the penetration of the guided object into the simulated object, under material removal, if applicable.
摘要翻译： 本发明的目的是一种用于模拟由用户引导的对象（以下称为工具）与虚拟三维对象的相互作用的触觉的方法，特别是模拟对象的表面的扫描，以及 /或如果适用的话，在引导物体穿透到模拟物体中。
-
公开(公告)号：US20200085405A1
公开(公告)日：2020-03-19
申请号：US16690001
申请日：2019-11-20
摘要： An exemplary device for detecting a heartbeat of a patient can be provided which can include a transmitter which can provide ultrasonic waves, a receiver that can receive Doppler-shifted ultrasonic waves, and a hardware analyzer coupled to the receiver and which can evaluate a particular moment of the heartbeat of the patient based on a time-dependent signal obtained from the receiver. The hardware analyzer device can comprise a spectrum analyzer configured to extract time-varying frequency component(s) from the time-dependent signal provided by the receiver, and a processing module which can evaluate the moment of the heartbeat based on a variation of at least one of the frequency components in time. The processing module can determine a window of interest (WOI) in time from the variation of the frequency component(s) in time, and the moment when the time-dependent signal provided by the receiver assumes a maximum within the WOI as the moment of the heartbeat.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.017 秒)
